An investment group based out of the USA is a wholly owned subsidiary of a large healthcare system. The firm engages in strategic investments across a wide variety of sectors to benefit the health system. The firm invests at a set pace with ~2 surgery centers being invested in per year and are currently looking to diversify their portfolio. The firm tends to invest in seed and pre-revenue rounds as their allocation size is on the smaller side, but is interested in revenue generating opportunities with smaller rounds.

The firm is particularly interested in technologies that can help them increase the quality of care, decrease the cost of care, and increase the access of services to populations which have been historically denied. Beyond that though, the firm is rather opportunistic within the healthcare IT, medical devices, healthcare services, and care delivery spaces and currently has no specific focus.

The firm requires that companies have some sort of relationship with the firm or have the endorsement of the senior management of the health system.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical company headquartered in Asia operating globally in terms of R&D, manufacturing, distribution and marketing, with a strong focus on prescription medicines. The firm’s corporate investment arm has offices in USA and Japan and actively makes strategic equity investments in early-stage companies that align with the firm’s business. The firm will invest between $1-5M in seed to mid-stage companies, with Series A being the sweet spot. The firm is open to global opportunities.

The firm is interested in opportunities that are synergistic with their research and development pipeline in neurology and oncology. The firm is interested in pharmaceutical drugs across various modalities, including but not limited to antibodies, peptides, nucleic acids, and cell/gene therapy. The firm is also interested in digital therapeutics, IT solutions, and diagnostics. Within neurology, the firm is strongly interested in (but not limited to) neurodegenerative diseases including Alzheimer’s Disease and Parkinson’s Disease as well as epilepsy and sleep disorders. Within oncology, the firm is interested in solid tumors (breast, liver, lung, etc).

The firm is a flexible investor and can act as a lead or follow-on investor. The corporate venture investment closely collaborates with the firm’s business development division and leverages its global network of pharmaceuticals, research universities, etc. to identify and collaborate with cutting edge opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences venture capital fund with offices in Asia currently manages two funds and is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

The firm is focused on Therapeutics and Medical Devices opportunities. The firm’s core focused therapeutic areas include oncology, immunology and CNS diseases, but is also opportunistic in other indications (modality agnostic) and willing to consider orphan indications. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular diseases.

The firm prefers management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A biotech early stage investment fund founded in 2016 and headquartered in Taipei, Taiwan invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

The firm does not have any specific requirements for companies and their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment partnership based in the USA is dedicated to providing impact investment capital to life science and healthcare companies in both public and private markets. The firm can invest from $1 – 50M depending on the stage of development of the company. The firm is open to global opportunities and has expertise with working in global markets.

The firm is most interested in therapeutics opportunities, and medical devices to a lesser extent. The firm looks for technologies that have the potential to make a significant impact to the global population. In therapeutics, the firm can look as early as pre-clinical to Phase I/IIa. For devices, the firm looks for those that are close to 510k FDA approval.

The firm invests in both publicly traded and privately owned companies. The firm prefers to work with experienced, transparent management teams with clearly demonstrated growth and defined (or capable of helping define) exit strategy. The firm prefers to lead and requires a board of directors seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A transatlantic investment firm based in the Netherlands with an additional operation in Boston, USA, is investing from a fund of over $250 million.  The firm prefers to invest in commercial stage diagnostics/medical technology companies. The investment size ranges from $5 million up to $30 million. The firm is seeking to make 2-3 investments over the next 6-9 months, targeting companies based in the U.S. and Europe.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices and Digital Health spaces. The firm is very opportunistic in terms of subsectors and indications. The firm does not look at therapeutics or biotech R&D service technologies. For diagnostics and medical devices, the firm is interested in companies with commercial-stage/revenue-generating products, but may also look opportunistically at earlier stage technologies. These may include 510K devices where the FDA clearance is very close and/or where reimbursement is the last hurdle and feel confident in the path to reimbursement. For digital health, the firm looks opportunistically at companies beyond the Series A stage. Historically, the firm was active in medical device companies developing orthotic and prosthetic devices, as well as peripheral vascular applications in cardiovascular diseases.

The firm focuses on investments in private companies and it will consider pre-revenue companies, depending on the opportunity. The firm prefers to invest in companies with experienced and committed management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm based in London, UK that focuses exclusively on healthcare seeks to invest £10M-£20M over the life of an investment, but initial investment can range from £1M-£5M. Investments are most commonly in the form of equity, although there is flexibility in regards to capital structure. The firm looks to make 2-3 investments per year in revenue-generating companies.

The firm is technology and indication agnostic, but intends to focus on innovative medical products and healthcare services that aim to improve or reduce the cost of care provision, including health IT, digital health and software, primary and acute care models, homecare and social care, chronic disease management, dentistry, cosmetic and aesthetics but also medical equipment, specialty pharma, imaging, CROs and diagnostics.

There are no formal pre-requisites for company’s or management teams in terms of level of experience. The firm will consider companies with products in the clinic as long as the company has at least one product that is on the market. The firm prefers to invest in companies who are headquartered or have a large presence in Europe. U.S.-based companies with a European angle will also be considered.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.